Halozyme Therapeutics — Jan 28, 2026 release

n, YoY Growth of 51% to 52% 1 Raises 2026 Financial Guidance Ranges: - Increases Total Revenue to $1,710 - $1,810 million, YoY Growth of 23% to 30% 2 - Increases Royalty Revenue to $1,130 - $1,170 million, YoY Growth of 30% to 35% 2 - Increases Adjusted EBITDA to $1,125 - $1,205 million 3,4 - Increases non-GAAP Diluted EPS to $7.75 - $8.25 3,4 Expands Drug Delivery Opportunity with Acquisition of Surf Bio and its Hyperconcentration Technology Conference Call Scheduled Today at 5:30am PT/8:30am ET SAN DIEGO, January 28, 2026 -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (“Halozyme” or the “Company”) today provided a business update, including providing preliminary unaudited 2025 revenue estimates and raising full year 2026 and multi-year financial guidance. The Company also announced it acquired Surf Bio, Inc. (“Surf Bio”), a biopharmaceutical company with an innovative, biologic hyperconcentration technology seeking to transform the delivery of antibodies and biologics, in December 2025. “Our increased multi-year guidance reflects both the strength of our core ENHANZE business and the exceptional momentum we built in 2025. In 2025, we expect royalty revenue growth to exceed 50% year ‑ over ‑ year, a clear demonstration of the strength of our business model and the durable demand for ENHANZE ‑ enabled products globally. In parallel, we significantly expanded new partnerships, signing three new ENHANZE collab